Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs Ozempic and Wegovy. Novo Nordisk, the manufacturer of both, recently shared that CagriSema may lead to 10 percent more weight loss than Wegovy.

The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under anesthesia.

The UK’s drug’s watchdog has warned people over the use of counterfeit medications which could contain insulin - with many using the drug for "aesthetic reasons".

A recent poll found that about 15.5 million Americans have used injectable diabetes medicines like Ozempic and Wegovy to lose weight.